Kornimate/medical-research-clean huggingface dataset:
end-range mobilization on time curve of pressure pain threshold

Conditions: Knee Osteoarthritis

Summary: pain in knee osteoarthritis (oa) represents increased pain intensity due to peripheral and central sensitivity. pressure pain threshold (ppt) is a widely applied technique for measuring the magnitude of peripheral and central sensitivity in knee oa. despite several manual therapy techniques has been proven to increase ppt in knee oa, the effect of end-range mobilization on the time curve of ppt has not been evaluated so far in knee oa. the aim of this study was to investigate the effect of end-range mobilization on the time curve of ppt and some function-related measures in knee oa.

knee osteoarthritis (oa) is the most common form of arthritis leading to a major disability worldwide. although many mechanisms may contribute to knee pain severity, the patient-reported hyperalgesia can be attributed to peripheral and central sensitivity in knee oa. amongst quantitative sensory testing methods, pressure pain threshold (ppt) measurement is a simple and commonly applied method for measuring somatosensory function in musculoskeletal disorders, just as in knee oa. many trials have presented lower ppt in knee oa compared to healthy controls underlining the presence of peripheral and central sensitivity. the different joint-based mobilization techniques may not only alleviate pain, but also increase pain tolerance to the locally applied mechanical pressure. positive results of these techniques on increase of ppt has been reported in knee oa; however, the time curve of ppt has not evaluated so far in knee oa. therefore, the aim of this study was to investigate the effect of end-range mobilization on the time curve of ppt and some function-related measures in knee oa.

Eligibility criteria:
inclusion criteria: * the clinical classification criteria of knee oa according to the american college of rheumatology * categorization of patients as end of range problem based on manual therapy * unilateral/bilateral symptomatic tibiofemoral knee osteoarthritis with radiographic evidence of kellgren-lawrence scale between 1 and 3 * pain during weight-bearing activities at least within 6 months * sufficient mental status exclusion criteria: * acute inflammation of the knee * class ii. obesity (body mass index, bmi\>35kg/m2) * severe degenerative lumbar spine disease (e.g. spondylolisthesis) * systemic inflammatory arthritic or neurological condition * physiotherapy/balneotherapy attendance or manual therapy within 3 months * intraarticular injections in the prior 12 months * use of walking aids * contraindication for manual therapy * complex regional pain syndrome * cognitive impairment

Keywords: musculoskeletal manipulations osteoarthritis, knee pain threshold
nasal olfactory stimulation and its effect on respiratory drive in preterm infants

Conditions: Apnea of Prematurity; Prematurity; Infant, Premature, Diseases

Summary: this trial analyzes the effect of an olfactory stimulation with vanilla or strawberry aroma compared to placebo on desaturations and bradycardia in preterm infants with apnea of prematurity. infants on continuous positive airway pressure (cpap) support will be included and the aroma will be applied to the inner surface of the cpap mask using designated scent pens. the trial uses a cross-over design. infants are randomised to begin the study with either aroma or placebo which will be applied into the breathing mask every 3 to 4 hours during 12 hours for each of the two intervention periods. identically looking pens with either aroma or placebo are used and patients, parents, medical staff and the study team are blinded to this allocation. infants are monitored with an oximetry sensor to measure peripheral oxygen saturation (spo2) and pulse rate.


Eligibility criteria:
inclusion criteria: * gestational age at birth: 23 0/7 to 31 6/7 weeks * postnatal age: \>72 hours old * respiratory support: ncpap * treatment with caffeine citrate for apnea of prematurity * written informed consent by one of the patient's parents exclusion criteria: * olfactory impairment such as choanal atresia * intraparenchymal intracranial hemorrhage or intraventricular hemorrhage with ventricular dilation * culture-proven sepsis during the study period or any acute clinical deterioration requiring an intervention such as intubation or a new start of antibiotic treatment. * severe congenital malformation adversely affecting life expectancy

Keywords: olfactory stimulation
pulmonary recruitment maneuver for postlaparoscopic shoulder pain

Conditions: Gynecologic Diseases

Summary: the aim of this clinical trial is to evaluate the efficacy and safety of different recruitment maneuvers for reducing postlaparoscopic shoulder pain.

shoulder pain after laparoscopy is common and its probable mechanism is residual co2 gas after surgery. the pulmonary recruitment maneuver can mechanically remove residual co2 and reduce pain. in literature, there are two different recruitment maneuvers, which was manual inflation of the lungs with positive pressure ventilation of either 40cmh2o or 60cmh2o at the end of surgery. however, the higher positive pressure may be associated with more chance of barotrauma. therefore, it is important to determine the lowest effective pressure for reducing postlaparoscopic shoulder pain. the aim of this clinical trial is to evaluate the efficacy and safety of different recruitment maneuvers (40cmh2o or 60cmh2o) for reducing postlaparoscopic shoulder pain.

Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopy for benign gynecologic diseases * patients aged 19-65 years * patients with american society of anesthesiology physical status i-ii * patients obtaining written informed consent exclusion criteria: * patients with chronic shoulder pain, chronic epigastric pain or chronic pain syndrome * patients with past history of pneumothorax or any pulmonary surgical history * patients with any shoulder surgery histories * patients who required to conversion to open surgery from laparoscopic surgery * patients who required to receive incidental upper abdominal surgeries due to adhesion and injury at upper abdominal cavity * patients with inability to understand or express 10 point visual analogue scale * intrauterine pregnant women
safety and efficacy study of torisel and liposomal doxorubicin for patients with recurrent sarcoma

Conditions: Sarcoma

Summary: the purpose of this study is to identify a safe dosing regimen for the combination of torisel and liposomal doxorubicin in patients with recurrent sarcoma. a secondary purpose of the study is to determine how effective this combination is for the treatment of recurrent sarcoma.

the effectiveness of treatments for recurrent sarcomas is quite limited. one hypothesis to explain the refractory nature of recurrent sarcomas is the existence of chemotherapy-resistant sarcoma stem cells.

Eligibility criteria:
inclusion criteria: * histologically confirmed sarcoma that is recurrent or refractory to conventional treatment * measurable disease by recist criteria * ecog (eastern cooperative oncology group) performance status \ 60% for children) * life expectancy greater than 3 months * adequate organ function * absolute neutrophil count at least 1,500 * platelets at least 100,000 * bilirubin less than 1.5 x upper limit of normal * ast (aspartate aminotransferase) and alt(alanine aminotransferase) less than 2.5 x upper limit of normal * creatinine less than 1.5 x upper limit of normal or creatinine clearance at least 60 ml/min/1.73 m2 * fasting serum cholesterol less than 350 * fasting serum triglycerides less than 400 * pt (prothrombin) or inr (international normalized ratio) less than 1.3 x upper limit of normal * normal urinalysis * ability to understand and sign the informed consent document exclusion criteria: * prior chemotherapy or radiotherapy within 3 weeks of entering the study (6 weeks for nitrosoureas or mitomycin c) * prior treatment with a tyrosine kinase inhibitor within 10 days of entering the study * history of pulmonary hypertension or pneumonitis * patients may not be receiving other investigational agents * prior therapy with rapamycin, rapamycin analogues, or tacrolimus * uncontrolled brain metastases * history of grade 3 or 4 hypersensitivity to macrolide antibiotics * concurrent treatment with immunosuppressive agents other than a stable (for more than 2 weeks) dose of corticosteroids * uncontrolled intercurrent illness * pregnancy or breast feeding * hiv-positive patients on combination antiretroviral therapy * grade 3 or 4 proteinuria

Keywords: osteosarcoma soft tissue sarcoma rhabdomyosarcoma leiomyosarcoma ewing's sarcoma chondrosarcoma liposarcoma malignant fibrous histiocytoma malignant peripheral nerve sheath tumor pleiomorphic sarcoma spindle cell sarcoma synovial sarcoma cancer stem cell
study of rv001v in biochemical failure following curatively intended therapy for localized prostate cancer

Conditions: Prostate Cancer Recurrent

Summary: this phase ii trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (bcr) within 3 years of radical prostatectomy (rp) or definitive rt and no distant metastasis or locoregional recurrence. the trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (rv001v).


Eligibility criteria:
main inclusion criteria: * biochemical recurrence (bcr) within 3 years of radical prostatectomy (rp) or definitive rt and no distant metastasis by standard ct imaging and bone scintigraphy, or locoregional recurrence (including lymph nodes) assessed by ct or multi-parametric magnetic resonance imaging (mri) and confirmed with negative biopsy in case of prior rt. * in case of bcr after rp all the following criteria should apply: a. psa ≥0.2 ng/ml, b. psa doubling time (psadt) \>3 months and \<12 months * in case of bcr after rt all the following criteria should apply: a. psa \>nadir + 2 ng/ml, b. psadt \>3 months and \<12 months * ecog performance status ≤2. * laboratory values obtained ≤30 days prior to first vaccination: hemoglobin ≥5.6 mmol/l; absolute granulocyte count ≥1.5 x 109 /l, platelets ≥100 x 109 /l., total bilirubin ≤1.5 x upper limit of normal (uln). * creatinine ≤1.5 x uln. * alanine aminotransferase (alt), aspartate aminotransferase (ast) and alkaline phosphatase (alp) ≤2.5 x uln. main exclusion criteria: * patients who are receiving androgen-deprivation therapy or considered a candidate for immediate anti-androgen deprivation therapy (adt) as judged by the investigator. * patients who have received prior adt are not eligible with the exception of those that received adt ≤36 months in duration and ≥9 months before randomization and administered only in the neoadjuvant/adjuvant setting. * patient is planned for salvage therapy with rt or radical prostatectomy. * castrate level of serum testosterone \<50 ng/dl at screening. * psa \>10 ng/ml

Keywords: biochemical relapse
single bundle anterior cruciate ligament reconstruction in active young men

Conditions: Anterior Cruciate Ligament Rupture

Summary: the clinical outcomes of anterior cruciate ligament reconstruction using free tendon achilles allograft are comparable to those using achilles allograft with bone block on its end.


Eligibility criteria:
inclusion criteria: * male subjects * subjects who had concomitant medial collateral ligament injury which was managed conservatively * subjects who had meniscus tear which was managed by partial meniscectomy exclusion criteria: * subjects who underwent a subtotal or total meniscectomy, meniscal repair, or meniscal transplantation due to meniscus injury * subjects who underwent an operation due to any concomitant ipsilateral ligament injuries * subjects who underwent microfracture or cartilage transplantation due to full thickness cartilage injury * female * subjects who were older than 45 * subjects who had histories of injuries on either knee

Keywords: anterior cruciate ligament achilles free tendon bone-tendon free tendon achilles allograft achilles allograft with calcaneal bone block on its end
validity study of a nasal valve implant

Conditions: Nasal Valve Collapse

Summary: the purpose of this study is to determine if an implant material can be injected to repair nasal valve collapse.


Eligibility criteria:
inclusion criteria: * has nasal valve collapse exclusion criteria: * pregnancy
addressing social determinants of health & diabetes self-management in vulnerable populations

Conditions: Diabetes

Summary: in this pilot and feasibility study, the investigator will randomize 100 african-american, hispanic, and/or medicaid (all race/ethnicities) patients from kpnw with a1c ≥ 8 to one of two 6-month interventions: 1) patient navigation only; or 2) patient navigation + diabetes self-management training. feasibility of a large-scale, pragmatic, randomized trial will be determined and preliminary effectiveness of treatment arms on a1c reduction among racial/ethnic minority and low-income patients with poorly managed diabetes will be examined.

the purpose of this feasibility study is to inform the design of a future large-scale, randomized trial that will test if there is added benefit to addressing both social and economic needs and diabetes self-management to improve diabetes management long-term among vulnerable populations. in this pilot, the investigator will randomize 100 african-american, hispanic, and/or medicaid (all race/ethnicities) patients from kaiser permanente northwest (kpnw) with a1c ≥ 8 and poor follow-up in primary care to one of two 6-month interventions: 1) patient navigation only; or 2) patient navigation + diabetes self-management training. in both study arms, kpnw practice-embedded patient navigators will screen for medical, social and economic needs and connect participants to internal and external resources. in the second study arm, navigators will also refer participants to community health workers (chws) embedded in local community-based organizations, who will deliver diabetes self-management training. feasibility of the full-scale trial will be based on several measures including recruitment, retention, success rate of referrals to navigators and chws, and whether medical, social, and/or economic needs are met. qualitative interviews will be conducted with various stakeholders to assess intervention acceptability and determinants of implementation. preliminary effects of a1c, diabetes-related care gaps, health care utilization, and medication adherence will also be examined. this pragmatic study design involves a collaborative effort among researchers, health system staff, health system senior leadership, and local community-based organizations. findings from the full-scale trial will contribute critical knowledge on the most effective, sustainable model of care for integrating lay health workers in the efforts to improve diabetes management among high risk patient populations.

Eligibility criteria:
inclusion criteria: * diabetes diagnosis * current kaiser permanente northwest member * african-american, hispanic/latino (english, spanish-speaking, or bilingual), and/or a medicaid recipient (from any racial or ethnic background) * age 18 or older * most recent hemoglobin a1c test of ≥ 8 * endorses 1 or more social and/or economic need on the your current life situation assessment exclusion criteria: * patients who are unable to provide informed consent due to cognitive or psychiatric impairment.
treatment with sglt-2 inhibitor for postoperative hyperglycemia in acute abdominal surgery - a randomized trial

Conditions: Postoperative Hyperglycemia; Stress Hyperglycemia

Summary: the aim of the study is to investigate the effect of an sglt-2 inhibitor on postoperative hyperglycemia after acute abdominal surgery in patients without diabetes


Eligibility criteria:
inclusion criteria: * - admitted to the ward after acute abdominal surgery (asap patient at slagelse hospital, omega patient at zealand university hospital) * at least two independent measurements of blood glucose above 7.7mmol/l within the first 48 hours after surgery * age of 18 to 85 * must be able to understand and sign informed content exclusion criteria: * patients diagnosed with diabetes mellitus * impaired kidney function (egfr \< 45ml/min) * severe liver disease (defined as transaminases above x 3 normal levels) * acute pancreatitis within the last two months or a history of chronic pancreatitis * participation in another pharmacological intervention trial * predictable poor compliance (for instance mentally impaired) * pregnancy or lactation (fertile women must have a negative serum or urine pregnancy test to participate) * allergy to study medication

Keywords: acute abdominal surgery sglt-2 inhibitor
the efficacy and safety of corticosteroids in combination with ruxolitinib in the management of checkpoint inhibitor pneumonia

Conditions: Severe Checkpoint Inhibitor Pneumonitis

Summary: this study is a prospective multicenter randomized controlled interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with ruxolitinib in the treatment of severe checkpoint inhibitor pneumonitis.


Eligibility criteria:
inclusion criteria: 1. 18 years old≤ aged ≤80 years old. 2. diagnosis of malignancy. 3. malignant tumors initially treated with immune checkpoint inhibitors (antibodies targeting pd-1, pd-l1, ctla-4, or new immune checkpoint inhibitors) in combination with or without chemotherapy. 4. diagnosis of grade 3 or 4 cip: cip severity at ctcae grade 3 or 4. 5. patients who and whose family members understand the study protocol, are willing to participate in the study and could provide written informed consent. exclusion criteria: 1. predicted life expectancy\<12 weeks. 2. any evidence of active or uncontrolled viral infection, including hepatitis b, hepatitis c and human immunodeficiency virus (hiv), or any clinical signs of bacterial, other viral, parasitic or fungal infection requiring treatment. 3. malignancy progression. 4. patients with other serious complications that may affect safety or adherence judged by the investigator. 5. any significant clinical and laboratory abnormalities judged by investigator that affect the safety evaluation. 6. patients can't fully understand the study protocol, arrangement and other study-related elements. 7. patients with evidence of severe liver or kidney dysfunction judged by investigator unsuitable for enrolment. 8. women who are pregnant, breast feeding or unable to use effective contraception during the study period and for 3 months after the completion. 9. patients who cannot comply with study treatment and follow-up according to the trial protocol.
the effect of vitamin d therapy on morbidity and moratlity in patients with sars-cov 2 infection

Conditions: Covid19; SARS-CoV Infection

Summary: the ongoing pandemic of sars cov-2 virus is calling for effective preventive and theraputic interventions. vitamin d has been shown to play immunemodulatory functions in human. low vitamin d levels have been linked to increased susciptability to infections especially the acute respiratory infections. this randomised controlled study aims to explore the effect of vitamin d administration on the outcome of sars- cov2 virus

background: coronavirus disease covid-19 is an ongoing pandemic and is causing avoidable fatalities worldwide. vitamin d plays an essential role in the immune system. vitamin d interferes with the majority of the immune systems cells such as macrophages, b and t lymphocytes, neutrophils and dendritic cells. we aim to find whether supplementation of vitamin d deficient diabetes with a single intramuscular cholecalciferol injection could improve the prognosis of those patients. patients and methods: this was a placebo controlled randomized prospective study, included cohorts of 40 diabetes elderly patients who got infected with sars-cov-2 compared with 16 elderly diabetes patients matched of the same age group who got infected with sars-cov-2 but given a placebo instead intramuscularly were used as a control. clinical, laboratory, treatment, and outcome data were recorded after six weeks of follow up especially icu admissions and fate of covid-19 disease.vitamin d was given as a single intramuscular injection during period of the study.

Eligibility criteria:
inclusion criteria: - elderly type ii diabetes adult with age more than 60 years males and females having deficient serum vitamin d levels (less than 25 ng/ml). diabetes patients recruited to the control group were only included in the study if not known to have cholecalciferol supplementation within last 6 weeks. all elderly vitamin d deficient diabetes patients were diagnosed with covid-19 when throat-swab specimens for sars-cov-2 pcr were positive. exclusion criteria: * patients with known history of renal stones, diagnosis of hypercalcemia with the past year, baseline serum total calcium more than 10mg/dl, established diagnosis associated with increase the risk of hypercalcemia (e.g. metastatic cancer, sarcoidosis, multiple myeloma, primary hyperparathyroidism), and current vitamin d supplementation moreover, other exclusion criteria included those with known malignancy, with organ transplant, and those with known chronic autoimmune diseases and lastly those on systemic steroid for any cause
nexium capsules helicobacter pylori specific clinical experience investigation

Conditions: Gastric Ulcer; Duodenal Ulcer; Gastric Mucosa-associated Lymphoid Tissue (MALT); Lymphoma Idiopathic Thrombocytopenic Purpura; Early Gastric Cancer

Summary: the purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for helicobacter pylori eradication with nexium + amoxicillin (ampc) + clarithromycin (cam), or nexium + ampc + metronidazole (mnz) in usual post-marketing use.

nexium capsules specific clinical experience investigation concerning helicobacter pylori eradication

Eligibility criteria:
inclusion criteria: * triple therapy for h.pylori eradication to stomach started after endoscopic treatment for gastric ulcer * triple therapy for h.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer * triple therapy for h.pylori eradication to stomach started after endoscopic treatment for gastric malt lymphoma * triple therapy for h.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura * triple therapy for h.pylori eradication to stomach started after endoscopic treatment for early gastric cancer exclusion criteria: - h.pylori negative at the time when the triple therapy is started

Keywords: triple therapy helicobacter pylori eradication nexium
ultrasound guided regional anesthesia for acute injury in low resource settings

Conditions: Pain Management; Acute Injuries

Summary: the purpose of this study is to determine feasibility, perceived utility and sustainability of training local providers in ultrasound guided regional anesthesia for acute pain management in a limited-resource conflict setting.

to the investigators knowledge, this is the first study of feasibility, perceived utility and sustainability of usra as a pain management tool in a low-resource conflict setting and is one of the only large studies to date to assess usra by local providers for emergent pain relief due to injury in patients presenting to an acute care center.

Eligibility criteria:
inclusion criteria: * participants were chosen by hospital administration exclusion criteria: * only chosen participants were included

Keywords: low resource conflict setting ultrasound guided regional anesthesia acute injuries pain management education ultrasound trauma emergency department